Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Three Biotechs Well-Positioned for M&A: Gilead, Celgene, and Biogen

April 14, 2015By Riley McDermid, Breaking News Sr. Editor The American biotech sector will see a continued boom in its merger and acquisition cycle after an unprecedented first quarter saw over $100 billion in deals, with companies like Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG), and Biogen, Inc. all poised to participate, said UBS […]

Read More »

BioRestorative Shutters Florida Office and Opens New HQ and Lab in New York

April 14, 2015By Alex Keown, Breaking News Staff MELVILLE, N.Y.– BioRestorative Therapies, Inc. a life sciences company developing adult stem cell-based therapies for various medical applications, moved its corporate and laboratory operations to Long Island from Jupiter, Fla., the company announced this morning. In 2014 BioRestorative Therapies (BRT) was awarded $500,000 in tax credits […]

Read More »

Merck & Co. Execs See Big Compensation Increases

April 14, 2015By Mark Terry, Breaking News Staff Kenilworth, N.J.-based Merck & Co. (MRK)’s recent Securities and Exchange Commission (SEC) filings indicate that CEO Kenneth Frazier will see an increase in total compensation of about 87 percent this year. In addition, Robert Davis, company chief financial officer, will see an increase of about 10 […]

Read More »

Incyte Targets Switzerland for a New Clinical Development HQ

April 14, 2015By Krystle Vermes, Breaking News Staff Delaware-based Incyte Corporation (INCY), an oncology-focused biopharmaceutical company, announced on April 14 that it will be establishing a European headquarters in Geneva, Switzerland. Incyte Europe S.a.r.l., as it has been titled, will conduct European clinical development operations. It will occupy approximately 9,000 square feet by mid-2015. […]

Read More »

The CementBloc welcomes 3 new creative leaders to its award-winning team

NEW YORK, April 14, 2015 /PRNewswire/ — The CementBloc has announced the addition of Robin Tzannes, Sharon Howard-Butler, and Marc Law to its creative leadership team. Photo –  Sharon Howard-Butler and Marc Law, formerly of Saatchi & Saatchi Health Sydney, join the agency as SVP, Creative Director, Copy, and VP, Associate Creative Director, Art, respectively. […]

Read More »

REGiMMUNE Announces Collaboration With JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells

Antigen-Specific Immunotherapy to Potentially Prevent or Delay Diabetes in Preclinical Model TOKYO, JAPAN–(Marketwired – Apr 14, 2015) – REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a research collaboration to develop an antigen-specific immunotherapy utilizing RGI’s proprietary αGalCer/liposome platform for immunological tolerance for […]

Read More »

Talent Exodus From Banks Continues as Healthcare M&A Thrives

April 14, 2015By Riley McDermid, Breaking News Sr. Editor Bankers are leaving their jobs at large investment firms for smaller, boutique outfits in a bid to get a piece of the $92.5 billion of U.S. healthcare merger activity already in 2015, as healthcare and biotech have boomed over the last 13 months, Reuters reported […]

Read More »

U.S. Solicitor General Intervenes Against Johnson & Johnson in DECN’s Long Running Patent Battle Over GenStrip 50

Interventions by the Solicitor’s Office to Protect the Rights of a Corporation Are Rare LOS ANGELES, CA–(Marketwired – Apr 14, 2015) – Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip™ 50, the FDA cleared Green Alternative Strip, specifically […]

Read More »

Banks see talent flee amid healthcare M&A boom

Pedestrians walk past the world headquarters of Pfizer in New York November 5, 2013. Reuters/Adam Hunger (Reuters) – Several high-ranking bankers have left their jobs at major investment banks in the last 13 months amid a surge in U.S. healthcare deal activity to seek better compensation at boutique investment banks as well as to participate […]

Read More »

Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares

DUBLIN, IRELAND–(Marketwired – Apr 13, 2015) – Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that it is offering to sell 12,000,000 of its ordinary shares in an underwritten public offering. Horizon Pharma plc also […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom